Histopathological Study of Metformin Effect on Parkinsonism Mice Model
DOI:
https://doi.org/10.32947/ajps.v25i5.1303Keywords:
Parkinson's disease, Rotenone, Metformin, histopathological studyAbstract
Background: Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Oxidative stress and neuroinflammation are major contributors to its pathogenesis. Metformin, a widely used antidiabetic agent, has shown neuroprotective potential in several neurological conditions.
Objective: To compare the histological changes between the groups of mice that received a prophylactic dose of metformin and those that did not, as well as to compare the effect of metformin when added to standard treatment.
Methods: Thirty male albino mice were randomly divided into six groups: (Group 1) control group; (Group 2) a rotenone induction group; (Groups 3) pre-treated with metformin three days before induction (500mg/kg);(Group 4) received metformin (500 mg/kg) ; (group 5) received L-DOPA/Carbidopa (100/25 mg/kg); and (group 6) received both drugs concurrently At the end of the 47-day study period, the animals were sacrificed, and their brains were harvested and fixed in 10% neutral buffered formalin for histological examination.
Results: Histopathological analysis showed that rotenone induced classical PD-related changes, including neuronal shrinkage, pyknotic nuclei, karyorrhexis, and marked activation of microglia and astrocytes. Prophylactic metformin administration significantly ameliorated these changes, while the combined treatment group demonstrated improved neuronal preservation compared to the standard therapy alone.
Conclusions: These findings support the potential neuroprotective role of metformin, both as a prophylactic and adjunctive agent to conventional therapy in PD.
References
1- Rai SN, Singh P. Advancement in the modelling and therapeutics of Parkinson’s disease. J Chem Neuroanat. 2020 ;104 :101752. doi: 10.1016/j.jchemneu.2020.101752
2- Zhu J, Cui Y, Zhang J, Yan R, Su D, Zhao D, et al. Temporal trends in the prevalence of Parkinson’s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 2024;5(7):e464–79. doi: 10.1016/S2666-7568(24)00094-1
3- Ou R, Lin J, Liu K, Jiang Z, Wei Q, Hou Y, et al. Evolution of apathy in early Parkinson’s disease: a 4-year prospective cohort study. Front Aging Neurosci. 2021; 12:620762. doi:10.3389/fnagi.2020.620762
4- Hommel ALAJ, Meinders MJ, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, et al. The prevalence and determinants of neuropsychiatric symptoms in late‐stage parkinsonism. Mov Disord Clin Pract. 2020;7(5):531–42. doi: 10.1002/mdc3.12968
5- Parkinson’s Disease in Iraq [Internet]. [cited 2025 Jan 16]. Available from: https://www.worldlifeexpectancy.com/iraq-parkinson-disease.
6- Abdullah AF, Niazi AD, Kareem AMA. Prevalence of Parkinson’s disease in Al-Kadhimiya district (Baghdad city): community-based study. Iraqi J Med Sci. 2005;4(2):179–186.
7- Safiri S, Noori M, Nejadghaderi SA, Mousavi SE, Sullman MJM, Araj-Khodaei M, et al. The burden of Parkinson’s disease in the Middle East and North Africa region, 1990–2019: results from the global burden of disease study 2019. BMC Public Health. 2023;23(1):107. doi: 10.1186/s12889-023-15018
8- Reichmann H, Csoti I, Koschel J, Lorenzl S, Schrader C, Winkler J, et al. Life style and Parkinson’s disease. J Neural Transm. 2022 Sep;129(9):1235–45. doi: 10.1007/s00702-022-02509-1
9- Becerra-Calixto A, Mukherjee A, Ramirez S, Sepulveda S, Sinha T, Al-Lahham R, et al. Lewy body-like pathology and loss of dopaminergic neurons in midbrain organoids derived from familial parkinson’s disease patient. Cells. 2023;12(4):625. doi: 10.3390/cells12040625
10- Ramesh S, Arachchige ASPM. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci. 2023;10(3):200. doi: 10.3934/Neuroscience.2023017
11- Azimullah S, Meeran MFN, Ayoob K, Arunachalam S, Ojha S, Beiram R. Tannic acid mitigates rotenone-induced dopaminergic neurodegeneration by inhibiting inflammation, oxidative stress, apoptosis, and glutamate toxicity in rats. Int J Mol Sci. 2023;24(12):9876. doi: 10.3390/ijms24129876
12- Lai S, Wang P, Gong J, Zhang S. New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis. PeerJ. 2023;11:e16635. doi: 10.7717/peerj.16635
13- 13.. Rocha SM, Bantle CM, Aboellail T, Chatterjee D, Smeyne RJ, Tjalkens RB. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice. Neurobiol Dis. 2022; 167:105685. doi: 10.1016/j.nbd.2022.105685
14- Van Laar AD, Webb KR, Keeney MT, Van Laar VS, Zharikov A, Burton EA, et al. Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy. npj Park Dis. 2023;9(1):121. doi:10.1038/s41531-023-00542-6
15- Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson’s disease patients: opportunities and choices. Postgrad Med. 2021;133(7):721–7. doi: 10.1080/00325481.2021.1936087
16- Lees A, Tolosa E, Stocchi F, Ferreira JJ, Rascol O, Antonini A, et al. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother. 2023;23(1):15–24. doi: 10.1080/14737175.2023.2176220
17- Gouda NA, Elkamhawy A, Cho J. Emerging therapeutic strategies for Parkinson’s disease and future prospects: A 2021 update. Biomedicines. 2022;10(2):371. doi: 10.3390/biomedicines10020371
18- Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Ashour NA, Jabir MS, Negm WA, et al. Metformin role in Parkinson’s disease: a double-sword effect. Mol Cell Biochem. 2024;479(4):975–91. DOI: 10.1007/s11010-023-04771-7
19- Karim LZA, Arif IS, Saady FAA. Metabolomics Of metformin’s cardioprotective effect in acute doxorubicin induced-cardiotoxicity in rats. Syst Rev Pharm. 2021; 12:100–9. doi:10.31838/srp.2021.3.18
20- Wang M, Tian T, Zhou H, Jiang SY, Jiao YY, Zhu Z, et al. Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson’s disease through Mfn2-cGAS signaling. J Neuroinflammation. 2024;21(1):81. doi: 10.1186/s12974-024-03072-0
21- Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of Parkinson’s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol. 2016;19(9): pyw047. doi: 10.1093/ijnp/pyw047
22- Numan IT, Mohamed NH, Ali ZK. Antioxidative effect of metformin on valproic acid induced hepatoxicity in male rats. Al Mustansiriyah J Pharm Sci. 2022;22(3):17–23. doi: https://doi.org/10.32947/ajps.v22i3.885
23- Arif IS, Al-Ezzi MI. The protective effect of metformin against doxorubicin induced cardiotoxicity in rabbits. Al Mustansiriyah J Pharm Sci. 2019;19(1):54–62. doi: https://doi.org/10.32947/ajps.v19i1.544
24- Ibrahim ZAH, Abdulrida MK, Razoqi RB. Assessment of Symptoms, Pregnancy Outcome, and Health-Related Quality of Life among PCOS women Treated with Myo inositol and Metformin. Al Mustansiriyah J Pharm Sci. 2023;23(3):273–84. doi: https://doi.org/10.32947/ajps.v23i3.1045
25- El-Sherbeeny NA, Soliman N, Youssef AM, Abd El-Fadeal NM, El-Abaseri TB, Hashish AA, et al. The protective effect of biochanin A against rotenone-induced neurotoxicity in mice involves enhancing of PI3K/Akt/mTOR signaling and beclin-1 production. Ecotoxicol Environ Saf. 2020; 205:111344. doi: 10.1016/j.ecoenv.2020.111344
26- Timmins P, Winter WJ, Srivastava SK, Bretnall AE, Wei C, Powers GL. Salts of metformin and method. US Patent US6039944A. 2000.
27- Hussain L, Masood I, Ahmad M, Ali MY, Saleem U, Hussain M, et al. Pharmacological and toxicological evaluation of methyl 4-hydroxy-2H-1, 2-benzothiazine-3-carboxylate 1, 1-dioxoide against haloperidol induced Parkinson like symptoms in animal model: in-vitro and in-vivo studies. Toxicol Appl Pharmacol. 2023; 477:116678. doi: 10.1016/j.taap.2023.116678
28- El-Ghaiesh SH, Bahr HI, Ibrahiem AT, Ghorab D, Alomar SY, Farag NE, et al. Metformin protects from rotenone–induced nigrostriatal neuronal death in adult mice by activating AMPK-FOXO3 signaling and mitigation of angiogenesis. Front Mol Neurosci. 2020; 13:84. doi: 10.3389/fnmol.2020.00084
29- Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice. Neuroscience. 2014;277 :747–54. doi: 10.1016/j.neuroscience.2014.07.046
30- Ryu YK, Go J, Park HY, Choi YK, Seo YJ, Choi JH, et al. Metformin regulates astrocyte reactivity in Parkinson’s disease and normal aging. Neuropharmacology. 2020; 175:108173. doi: 10.1016/j.neuropharm.2020.108173
31- Rocha SM, Bantle CM, Aboellail T, Chatterjee D, Smeyne RJ, Tjalkens RB. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice. Neurobiol Dis. 2022; 167:105685. doi: 10.1016/j.nbd.2022.105685
32- Abdel-Salam OME, Omara EA, Youness ER, Khadrawy YA, Mohammed NA, Sleem AA. Rotenone-induced nigrostriatal toxicity is reduced by methylene blue. J Neurorestoratology. 2014; 2:65–80. DOI https://doi.org/10.2147/JN.S49207
33- Himalian R, Singh SK, Singh MP. Ameliorative role of nutraceuticals on neurodegenerative diseases using the Drosophila melanogaster as a discovery model to define bioefficacy. J Am Nutr Assoc. 2022;41(5):511–39. doi: 10.1080/07315724.2021.1904305
34- Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson’s disease. Lancet. 2024;403(10423):293–304. doi: 10.1016/S0140-6736(23)01478-2
35- Mao Q, Qin W zhi, Zhang A, Ye N. Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease. Acta Pharmacol Sin. 2020;41(4):471–82. doi:10.1038/s41401-020-0365-y
36- Innos J, Hickey MA. Using rotenone to model Parkinson’s disease in mice: a review of the role of pharmacokinetics. Chem Res Toxicol. 2021;34(5):1223–39. doi: 10.1021/acs.chemrestox.0c00522
37- El Mahdy EM, Gamal M, Aboulhoda BE, Al Dreny BA, Shamaa A, Rashed L, et al. Amelioration of rotenone-induced Parkinson’s disease: comparing therapeutic role of erythropoietin versus low-level laser activation of mesenchymal stem cells (an in vivo and in vitro study). Animal Cells Syst (Seoul). 2023;27(1):272–86. doi:10.1080/19768354.2023.2273467
38- Elshebiney S, Abuelfadl D, Abdel-Salam O. Neurochemical and histological brain alterations after tramadol administration to rotenone-induced Parkinson’s disease in rats. Egypt J Forensic Sci Appl Toxicol. 2020;20(1):15–32.
39- Blossom V, Ullal SD, Rai R, Massand A, Kumar CG, Joy T, et al. Effect of metformin on the neuronal morphology of frontal cortex and hippocampal regions in lipopolysaccharide induced neuroinflammation in male Wistar rats. Transl Res Anat. 2025; 38:100365.
40- Loan A, Syal C, Lui M, He L, Wang J. Promising use of metformin in treating neurological disorders: biomarker-guided therapies. Neural Regen Res. 2024;19(5):1045–55. doi: 10.4103/1673-5374.385286
41- Xing C, Liu S, Wang L, Ma H, Zhou M, Zhong H, et al. Metformin enhances endogenous neural stem cells proliferation, neuronal differentiation, and inhibits ferroptosis through activating AMPK pathway after spinal cord injury. J Transl Med. 2024;22(1):723. doi: 10.1186/s12967-024-05436-9
42- Mendonça IP, de Paiva IHR, Duarte-Silva EP, de Melo MG, da Silva RS, do Nascimento MIX, et al. Metformin improves depressive-like behavior in experimental Parkinson’s disease by inducing autophagy in the substantia nigra and hippocampus. Inflammopharmacology. 2022;30(5):1705–16. doi: 10.1007/s10787-022-01043-6
43- Demaré S, Kothari A, Calcutt NA, Fernyhough P. Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system. Expert Rev Neurother. 2021;21(1):45–63. doi: 10.1080/14737175.2021.1847645
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Esraa Hussein Ali, Ghaith Ali Jasim, Wassan Abdul Kareem Abbas
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
